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Abstract.  We have examined the immunocytochemical 
localization of protein kinase C (PKC) in NIH 3T3 
cells using mAbs that recognize Type 3 PKC.  In con- 
trol cells, the immunofluorescent staining was similar 
with mAbs directed to either the catalytic or the 
regulatory domain of PKC.  Type 3 PKC localized in a 
diffuse cytoplasmic pattern, while the nuclei were ap- 
parently unstained. Cytoskeletal components also were 
stained. Treatment of the cells with phorbol  12- 
myristate 13-acetate  (PMA) resulted in a redistribution 
of PKC with a specific increase in nuclear PKC.  Com- 
pared to control cells, the staining with the anticata- 
lytic domain mAbs changed markedly, covering the 
entire cell surface. In contrast, the staining by the an- 
tiregulatory domain mAb did not cover the cell sur- 
face and the nuclei remained unstained; these results 
suggest that PKC activation leads to a conformational 
change of the regulatory domain such that the epitope 
recognized by the antiregulatory domain mAb is not 
readily accessible. 
We have demonstrated by three criteria that PMA 
treatment specifically increased PKC in the nucleus: 
(a) immunofluorescent staining in isolated nuclei in- 
creased; (b) Western  blots showed that our mAbs de- 
tected only one protein, the 82-kD PKC, whose level 
increased in nuclear lysates from PMA-treated cells; 
and (c) PKC activity increased in nuclear lysates.  In 
fractionation studies we demonstrated that PKC 
specifically localized to the nuclear envelope fraction. 
These results demonstrate that PMA activation leads 
to a rapid redistribution of Type 3 PKC to the nuclear 
envelope, and suggests  that this isozyme may play a 
role in mediating PKC-induced changes in gene ex- 
pression. 
p 
ROTEIN kinase C (PKC)' is involved in the regulation 
of many cellular processes, including differentiation, 
hormone and neurotransmitter release, and gene acti- 
vation. Cloning studies have demonstrated that PKC is a fam- 
ily of closely related genes which encode a number of iso- 
zymes. Initially, three different PKC genes (or,/3, 3") were 
found; additional cDNA clones (tS, e, ~') have subsequently 
1. Abbreviations  used in this paper: PBA, PBS containing 1% BSA; PDBu, 
phorbol dibutyrate; PKC, protein kinase C; PMA, phorbol 12-myristate 13- 
acetate. 
2. We were unable to precisely assess the percent of total PKC activity repre- 
sented in the nuclear fraction after PMA treatment of the cells. We observed 
in seven experiments that the total  picomoles of PKC activity recovered 
from the PMA-treated cells was only 50-70% of the total activity from the 
control cells. This was not due to incomplete extraction of PKC membrane 
activity from PMA-treated cells, since we verified by immunoblotting that 
our NP-40 extraction procedure removed all  the immunoreactive Type 3 
PKC from the membrane fractions (data not shown). PMA treatment did 
not alter the migration of PKC on the DEAE columns, since elution of the 
columns with increasing NaCI concentrations did not improve the recovery 
of PKC.  Furthermore,  immunoblots did  not reveal the presence of PKC 
fragments. This indicates that the decrease in PKC is not due to proteolysis. 
Thus, the reason for the decreased recovery of PKC activity from PMA- 
treated cells is not readily apparent. 
been isolated. The or, ~ and 3' gene products (also referred 
to as Types 3, 2, and 1 PKC, respectively) have  been purified 
from a variety of different cells and tissues, and the tS, e, and 
~- products have been obtained from expression of the corre- 
sponding cDNA clones (for review, see reference 47). 
The isoforms are highly homologous and all possess ki- 
nase and phorbol ester binding activities. The biochemical 
characterization of  all the PKC isozymes is not complete, but 
some differences have been demonstrated. We and others (18, 
22, 35, 38, 67) have isolated antibodies specific for the c~, ~, 
and 3' isozymes, indicating that the proteins have unique anti- 
genic determinants. The isozymes vary in their requirements 
for enzymatic activity as well. Jaken and Kiley (25) demon- 
strated that Type 1 PKC is less calcium dependent than Types 
2 and 3. The Type 3 enzyme is more fully activated by ara- 
chidonic acid than are Types  1 and 2 PKC (59). Ido et ai. 
(23) showed that the EGF receptor is phosphorylated most 
rapidly by Type 3 PKC in vitro suggesting that the different 
PKC species may have different substrate  proteins.  These 
results suggest that the different forms of PKC may mediate 
different cellular functions in vivo. However, the modes of 
activation within cells and the exact physiological substrates 
of the individual isozymes are not yet known. 
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be a determinant of isozyme function, by regulating accessi- 
bility  to  substrates.  Differential  expression  of  isozymes 
within brain regions has been demonstrated (21, 56, 60). For 
example, in brain, Type 1 (3') is highest in the cerebellum 
and hippocampus, while Type 2 (/~) is highest in the cerebral 
cortex (60). 
Substrate accessibility and thus isozyme function may also 
be regulated by isozyme localization to different subeellular 
compartments.  PKC activity in control cells  is  primarily 
found in the  100,000-g  supernatant fraction. Activation of 
PKC leads to a redistribution of enzyme activity to the mem- 
brane fraction (for review,  see reference 46).  There are a 
number of unanswered questions concerning PKC redistri- 
bution and the role of the individual PKC isozymes. First, 
it is not known whether redistribution is identical for all the 
isoforms. For example, differential sensitivity to activators 
such as diacylglycerols may regulate isozyme activation and 
redistribution.  Second,  the  membrane compartment(s)  to 
which  PKC  becomes  associated  have  not  been  clearly 
identified by either biochemical or immunological analysis. 
For example, several studies have examined nuclear localiza- 
tion of PKC with varying results (15, 17, 34, 36).  Some of 
the variability among these reports may be explained by the 
antibodies or the cell types used. In addition, differential lo- 
calization of PKC isozymes may help explain some of the 
differences in these reports. To date, specific PKC isozyme 
localization to the cell nucleus has not been reported. 
One approach to answering these and other questions con- 
cerning isozyme function is with type-specific mAbs. Such 
reagents allow the examination of the individual isozymes 
and  their  unique  properties.  We  have  developed  highly 
specific mAbs to Type 3 PKC (38).  In this and the accom- 
panying article (26), we have used these mAbs to study the 
specific cellular localization of Type 3 PKC in cells. In this 
work, we examined the localization of Type 3 PKC in control 
and phorbol  12-myristate 13-acetate- (PMA) treated NIH 
3T3 cells. Furthermore, using three different techniques, we 
have observed the phorbol ester-induced association of Type 
3 PKC with nuclei. Nuclear subfractionation indicated that 
the bulk of the nuclear enzyme is associated with nuclear 
envelopes. 
Materials and Methods 
Materials 
Antibodies and their sources were as follows: rat anti-tubulin (Sera-Lab, 
Westbury, NY); FITC-labeled goat anti-mouse lgG (Kirkegaard &  Perry 
Laboratories, Gaithersborg, MD); TRITC-labeled goat anti-rat IgG (Cap- 
pel Laboratories, Malvern, PAL PMA was from Sigma Chemical Co. (St. 
Louis,  MO).  Gelvatol  was  from  Monsanto Co.  (St.  Louis,  MO).  The 
anti-PKC mAbs were as described in reference 38 and were from ammo- 
nium sulfate-precipitated hybridoma culture media. 
Methods 
Immunocytofluorescence. NIH 3T3 cells were plated on glass coverslips 
at 2  ×  104 cells per coverslip and cultured in DME supplemented with 
10%  FCS. For experiments involving phorbol ester treatment, cells were 
treated with 200 nM PMA in 0.1% DMSO. Cells were fixed by dipping in 
-20°C acetone and washed three times in PBA (PBS containing 1% BSA 
and 0.2% sodium azide). Identical results were obtained with fixation in 4% 
paraformaldehyde followed by permeabilization with 0.1%  Triton X-100. 
Fixed cells were incubated for 30 min at room temperature with anti-PKC 
mAbs diluted in PBA, washed three times with PBA, incubated in FITC- 
or TRITC-labeled second antibody for 30 rain, and washed with PBA. For 
nuclear preparations, the nuclear pellet was washed once in 10 mM Tris, 
pH 7.5,  containing 10 mM NaCI,  10%  sucrose, and  1 mM MgCI2,  and 
resuspended in PBA and cytospun at 250 rpm for 5 min onto glass slides. 
The nuclei were fixed by dipping in  -20°C methanol and stained as de- 
scribed for the intact cells. The coverslips were mounted on slides with Gel- 
vatol.  Fluorescence microscopy was carried out with a Zeiss Photomicro- 
scope II using a 25x objective. Photo micrographs were made using Kodak 
Tri-X Pan film. 
Cytoskeleton Preparations. Cytoskeletons were prepared using 100 mM 
Pipes buffer, pH 6.9, containing 0.2% Triton X-100, 1 mM EGTA, 2.5 mM 
GTP, and 4% polyethylene glycol 8,000, as described in references 49 and 
50. The cytoskeletons were fixed in I% paraformaldehyde for 10 min and 
stained as described for whole cells. In experiments not shown, cytoskele- 
tons from control and PMA-treated cells were prepared in Pipes buffer con- 
raining 0.05, 0.1, 0.2, and 0.5 % Triton X-iO0. In all cases no differences  were 
observed in nuclear staining in the cytoskeletons from PMA-treated cells, 
as compared to the control. The same experiment was also carried out using 
the modified Pipes cytoskeleton buffer described by Jaken et al. (26).  No 
change in nuclear staining in cytoskeletons from PMA-treated cells was ob- 
served under these conditions as well. 
Subcellular Fracfionation.  3T3  cells grown on 150-mm plates were 
treated with either 0.1%  DMSO (control) or 200 nM PMA for 10 min at 
37°C.  The cells were washed twice with saline and incubated for 30 min 
on ice with saline containing 1 mM EDTA.  Cells were removed from the 
plates using a Pasteur pipette, centrifuged at 500 g and washed twice with 
saline. The cell pellet was resuspended in nuclei buffer (10 mM Tris, pH 
7.5,  10 mM NaCI) containing 0.1% Triton X-100, homogenized 10x  in a 
Dounce homogenizer with a tight-fitting pestle and spun at 500 g for 5 rain. 
The resulting supernatant, determined to be free of nuclei as judged by light 
phase microscopy, was centrifuged at 100,000 g for 60 min. The 100,000-g 
pellet was resuspended in DEAE column buffer (20 mM Tris, pH 7.5, 2 mM 
EDTA, 0.5 mM EGTA, 5 mM DTT) containing 1% NP-40 and rocked for 
1 h at 4°C. Neither this pellet nor the 100,000-g supernatant contained lamin 
B,  as determined by Western blots. The 500-g nuclear pellet was resus- 
pended in nuclei buffer and layered over 45% sucrose in nuclei buffer and 
centrifuged at i,660 g for 30 rain. The nuclear pellet was washed twice in 
nuclei buffer containing 10% sucrose and 1 mM MgCI2,  and resuspended 
in DEAE buffer for Western blots, 1 mM KHCO3 for adenylate cyclase as- 
says, or in DEAE buffer containing 1% NP-40 for PKC assays. In experi- 
ments not shown, we established that 1% NP-40 (or Triton X-100) was re- 
quired to extract PKC activity  from nuclear and  nonnuclear membrane 
fractions. Treatment with either 0.1 or 0.2 % detergent extracted no PKC ac- 
tivity from these fractions, and 0.5% detergent extracted only 30% of the 
activity extracted by 1% detergent. 
In our initial experiments, the cells were homogenized in the complete 
absence of Triton X-100. Using this method, it was necessary to homogenize 
the cells 45-55x  in a Dounce homogenizer with a tight-fitting pestle. We 
were able to demonstrate PMA-induced PKC nuclear localization under 
these conditions; however, we found that our yield of nuclei was quite low. 
We, therefore, included 0.1%  Triton X-100 in the homogenization buffer, 
which allowed us to decrease the homogenization pestle strokes and to in- 
crease our nuclei recovery to >90%. 
Nuclear Envelope Preparations.  Nuclear envelopes were prepared as 
described in reference 33. Briefly,  nuclei were resuspended in STM buffer 
(250 mM sucrose, 50 mM Tris, pH 7.5,  5 mM MgSO4), incubated with 
RNase and DNase, followed by extraction in 1.6 M NaCI and 1%/3-mereap- 
toethanol (vol/vol), 
PKC Assays. The nuclear and 100,000-g membrane detergent extracts, 
and the  100,000-g  supernatants were applied to  1.0 ml DEAE columns, 
washed with DEAE buffer, and eluted with DEAE buffer containing 120 
mM NaCI. Samples were assayed for kinase activity either in the presence 
of 0.8 mM CaCI2 and 200 nM PDBu, or in the presence of CaCI2,  PDBu, 
and  100/~g/ml phosphatidylserine, as described in reference 38. 
Immunoblots.  Western blots were carried out as previously described 
(38).  Blots were erased using the procedure of Kaufmann et al. (33). 
Adenylate Cyclase. Adenylate cyclase was assayed as described by Saio- 
mon (57) on fractions from both control and PMA-treated cells, in the ab- 
sence of detergents. 
Superoxide Dismutase. Superoxide dismutase (1) was assayed in 96-well 
plates containing, in a total volume of 250 p.l, 50 mM "Iris, pH 7.8, 20 mM 
EDTA, 2.5 ~g/ml riboflavin, 75/zg/ml nitro blue tetrazolium, and 0-100 p,g 
of each of the subcellular fractions, The plates were incubated for 10 rain 
at room temperature on a fluorescent light box, and color development was 
measured on a Titertek multisean plate reader with a 600-nm filter. 
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nuclear matrix polypeptides (30) were subjected to two-dimensional IEF/ 
SDS-PAGE. Individual polypeptides were excised and injected into chick- 
ens or guinea pigs according to the schedule previously described (12). An- 
tibodies against the nuclear envelope lamins and the 38-kD nucleolar poly- 
peptide B23 have been previously described (12). The antibody against the 
62-kD  nuclear matrix/chromosomal  scaffold polypeptide is described by 
Newitt, J., J.  Shaper, and S.  Kaufmann (manuscript in preparation). 
Results 
Cellular lmraunofluorescence 
In an earlier study (38), we reported on the characterization 
of several mAbs to Type 3 PKC: M4, a mAb that recognizes 
the catalytic domain of Type 3 PKC; M7, an anticatalytic do- 
main mAb that recognizes an epitope common to both Types 
2 and 3 PKC; and M9, a mAb directed against the regulatory 
domain of Type 3 PKC. In this study we have used these 
mAbs  to  follow the  immunocytochemical localization of 
PKC in NIH 3T3 cells; McCaffrey et al. (43) reported that 
NIH 3"1"3 cells contain only c~ (Type 3) PKC. The cells were 
fixed, permeabilized, and stained with the anticatalytic Type 
3 PKC mAb M4 (Fig.  1). In control cells, the staining was 
diffuse and localized to the cytoplasm. The nuclei were visi- 
ble due to the absence of staining (Fig.  1 A). Treatment of 
the cells with 200 nM PMA for 10 min markedly changed 
the staining pattern (Fig. 1 B). The M4 immunofluorescence 
covered the entire surface of the cells, and the nuclei were 
no longer apparent. The staining pattern of cells treated with 
4~ phorbol 12,13-didecanoate, a biologically inactive tumor 
promoter,  was  identical to  that of control cells  (data not 
shown). On Western blots, M4 recognized the 82-kD PKC 
from both control and PMA-treated cells (see Fig. 5 A). 
Similar  staining under  each  of the  cell  treatments de- 
scribed (control or  10 rain PMA) was observed with M6 
(data not shown) and M7,  two other anticatalytic domain 
PKC mAbs (Fig.  1, C and D). After a  10-rain PMA treat- 
ment, the M7 staining covered the cell surface (Fig.  1 D). 
The antiregulatory domain mAb M9 stained control cells in 
a pattern similar to that of M4 and M7 (Fig. 1 E). The M9 
immunoreactivity was localized to the cytoplasm, but the 
staining was more fibrous in appearance than that obtained 
with M4. After a 10-min PMA treatment, a decrease in the 
uniform cytoplasmic immunofluorescence was seen as com- 
pared to control (Fig.  1 F). In contrast to the anticatalytic 
domain mAb staining pattern, the antiregulatory domain M9 
staining after PMA treatment did not cover the cell surface, 
and the nuclei remained unstained. 
We verified that the staining by the PKC mAbs was specific 
using competition experiments (Fig.  2).  Preincubation of 
M4 with rat brain PKC decreased the immunofluorescent 
staining in the cells. In ELISA assays, we showed that this 
preincubation of the mAbs also eliminated their reactivity 
with PKC purified from rat brain (data not shown). 
Cytoskeletal Immunofluorescence 
As with the REF52 cells (26), we examined immunofluores- 
cent staining in 3T3 cytoskeletal preparations. Immunoblot- 
ting experiments demonstrated that the mAbs reacted only 
with  the  82-kD  PKC  protein  in  these  detergent,  EGTA- 
extracted preparations (data not shown). The cytoskeletal ex- 
tracts from control cells were double-stained with either M4 
or M9 and a  rat antitubulin antibody (Fig. 3).  Incubation 
with  the  tubulin  antibody resulted  in  bright  microtubule 
staining (Fig. 3, B and D), and verified the cytoskeletal ex- 
traction procedure. Actin microfilaments also were present, 
as shown by phalloidin staining (data not shown). Both M4 
and  M9  stained these  cytoskeletal preparations,  although 
greater staining was observed with M9. For both mAbs, the 
staining patterns appeared fibrous, and the nucleus stained 
lightly. The staining pattern in cytoskeletal preparations from 
PMA-treated cells was not significantly different from the 
control cell preparations. 
Nuclear Localization 
Using the biochemical techniques of Western blots and ki- 
nase assays, we observed in our preliminary experiments that 
PMA treatment caused an increase in PKC activity and im- 
munoreactivity in the  100,000-g crude particulate fraction 
(which includes nuclei) of the cells (data not shown). The 
M4 and M7 immunofluorescent staining patterns of PMA- 
treated cells covered the entire cell surface and suggested that 
the localization of PKC may include the nucleus. We, there- 
fore, decided to examine nuclear localization of PKC in more 
detail, by fractionating control and PMA-treated cells into 
nuclear,  100,000-g  supernatant and  100,000-g  nonnuclear 
membrane fractions. The purity of the nuclei preparations 
was determined by adenylate cyclase and superoxide dismu- 
tase (SOD) assays, as well as by electron microscopy. The 
level of adenylate cyclase, a plasma membrane enzyme, in 
the nuclear lysates was <5% of that seen in the  100,000-g 
pellet fraction. Cytosolic contamination was measured by 
superoxide dismutase activity. Essentially no superoxide dis- 
mutase activity was measured in our nuclear fractions. Elec- 
tron microscopic examination showed that the preparations 
contained intact nuclei, with some nuclei ('~20%, based on 
visual inspection) having broken nuclear membranes (Fig. 4 
A).  Furthermore,  the  nuclei  were  relatively free of con- 
taminating organelles. 
PKC localization to the nuclear fraction was assessed in 
three ways:  immunofluorescence on isolated nuclei, direct 
assay for enzyme activity, and Western blotting of isolated 
nuclei.  First,  in  immunofluorescence experiments,  nuclei 
isolated from control cells showed little staining with M4 
(Fig. 4 B). In contrast, PMA treatment of the cells increased 
significantly the immunoreactivity of M4 in the nuclei (Fig. 
4 C). The staining pattern covered the surface of the nuclei 
in a punctated manner and the intensity was somewhat heter- 
ogeneous among the nuclei. 
Second, PKC activity was assayed in nuclear lysates. In 
preliminary experiments,  we established that recovery of 
PKC activity from the nuclear lysates required detergent ex- 
traction (data not shown).  Purified nuclei were extracted 
with 1% NP-40, and PKC activity in the nuclear extracts was 
measured after DEAE chromatography. Table I shows that 
in control cells, the specific activity of the nuclear fraction 
was  low,  380 pmol/min per  mg,  and nuclear activity ac- 
counted for only  1-4%  of the total cellular PKC activity. 
After PMA treatment, however,  the specific activity in the 
nuclear fraction increased 10-20-fold. This activity was ab- 
solutely dependent on the presence of calcium and phos- 
pholipid. 2 The activity of the  100,000-g  (excluding nuclei) 
pellet  also  increased with a  concomitant decrease  in  the 
100,000-g supernatant fraction, as expected. 
Leach et al. lmmunocytochemical Localization  of PKC in NIH 3T3 Cells  687 Figure 1. Type 3 PKC immunofluores- 
cence in 3T3 cells. NIH 3T3 cells were 
treated with (A, C, and E) 0.1% DMSO 
(control)  and (B, D,  and F) 200 nM 
PMA for 10 min. Cells were fixed and 
stained as described in Materials  and 
Methods  using mAb M4 (A and B), 
M7 (C and D), or M9 (E and F). G, 
control cells without primary antibody. 
Bar,  14/~m. 
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brain PKC. M4 was preincubated with PBA (A) or PKC partially 
purified from rat brain (B) for 30 min at room temperature. Staining 
of fixed cells was then carried out as described in Materials and 
Methods. Bar, 20 #m. 
Third, the presence of PKC in the nucleus was assessed 
in Western blots (Fig. 5). In all the cell fractions, including 
the nuclear preparations,  M4 recognized only one protein, 
which co-migrated with the 82-kD PKC purifed from rat 
brain. M7 gave identical results to M4 on Western blots (data 
not shown).  Type 3 PKC levels increased in the  100,000-g 
(nonnuclear) pellet of PMA-treated cells, with a concomitant 
decrease  in  the  100,000-g  supernatant  immunoreactivity 
(Fig. 5 B). Nuclear lysates from control cells contained little 
of the 82-kD immunoreactivity (Fig. 5 C, lane 1), which was 
consistent  with  our  biochemical  and  immunofluorescent 
results. However, the amount of 82-kD PKC increased in the 
nuclei prepared from PMA-treated cells (Fig. 5 C, lane 2). 
Densitometric scanning of the autoradiograms indicated that 
PMA treatment increased the level of Type 3 PKC '~30-fold 
in the nuclear fraction. 
Using either M4 or M7,  the presence of the 45-kD cata- 
lytic domain  of PKC,  which  is  recognized by both  these 
mAbs, was not detected. This was true for all the subcellular 
fractions from both control and PMA-treated cells. In West- 
ern blots using M9, the presence of 82-kD PKC was not de- 
tected.  This  result  was  not  surprising,  since  our  earlier 
studies demonstrated that the antiregulatory domain mAb 
M9  reacts poorly with denatured 82-kD PKC on Western 
blots. However, we also did not observe the presence of the 
35-kD regulatory domain of PKC, which is recognized by 
M9 on Western blots (38). Overall, these results demonstrate 
the presence of the 82-kD holoenzyme, but not PKC frag- 
ments, in the cellular fractions, including the nuclei, of con- 
trol and PMA-treated cells. 
To examine further the nuclear localization of PKC, we 
fractionated nuclei from untreated and PMA-treated cells as 
described  by  Kaufmann  (31).  This  method  separates  in- 
tranuclear proteins (including the nucleoli), DNA and RNA, 
from nuclear envelopes. When these fractions were probed 
with M4,  only the nuclear envelope fraction of the PMA- 
treated cells contained the 82-kD PKC (Fig.  5  C,  lane 8). 
When nuclear PKC in control cells was detected, it was al- 
ways found in the nuclear envelope fraction as well. We did 
not detect the presence of PKC in either the RNase/DNase 
fractions (Fig. 5 C, lane 3 and 4) or high salt extracts (Fig. 
5  C, lanes 5 and 6). We confirmed the effectiveness of the 
nuclear separation by probing with an antibody to lamin B, 
a 67-kD nuclear envelope protein (Fig. 5 D). The lamin B 
polyclonal antibody recognized a 67-kD protein in the nu- 
clear lysates and the envelope fractions, but not in the in- 
tranuclear protein fractions. These results demonstrate that 
Type 3 PKC cofractionates with lamin B, a nuclear envelope 
polypeptide. We also probed the blots with antibodies to a 
38-kD nucleolar structural protein and to a 62-kD intranu- 
clear matrix protein. These proteins were present in the high 
salt nuclear extracts and nuclear lysates (data not shown). 
These experiments confirmed the efficiency of our fraction- 
ation protocol and demonstrated that cofractionation of PKC 
with nuclear envelope proteins was not due simply to incom- 
plete separation of the nuclear fractions. 
Discussion 
The role of each of the PKC isozymes in cellular transduc- 
tion pathways is not known. These proteins are highly ho- 
mologous in their amino acid sequence, yet differences in 
their immunological and biochemical properties exist and 
may be important determinants of isozyme function. These 
properties  include  substrate  specificity,  cofactor  require- 
ments, as well as tissue distribution and subceUular location. 
Experiments to determine the role of the individual isozymes 
have been complicated by the lack of type-specific assays, re- 
agents, and inhibitors. To study the role of an individual iso- 
zyme, we have prepared mAbs that are specific for Type 3 
PKC and have used them to study the subcellular localization 
of this  isozyme.  We  observed  cytosolic and  cytoskeletal 
staining in control cells, and we clearly demonstrated that 
PMA treatment causes a  redistribution of PKC to the nu- 
cleus. This result has important implications in understand- 
ing the role of PKC in signal transduction and regulation of 
specific gene expression. 
In control NIH 3T3 cells,  PKC localization detected by 
mAbs directed towards either the catalytic or regulatory do- 
mains of PKC was similar.  A diffuse, cytoplasmic staining 
was observed with little or no nuclear staining. Recently, Ito 
et ai.  (24) demonstrated that Type 2  PKC mAbs stain un- 
treated human leukemia cells in a diffuse cytosolic pattern. 
Leach et al. lramunocytochemical Localization of PKC in NIH 3T3 Cells  689 Figure 3. Immunofluorescence of 3T3 microtubule cytoskeleton preparations. Cytoskeletons were prepared, fixed, and incubated with rat 
anti-tubulin  and mouse anti-PKC  mAbs (M4 or M9) followed by TRITC-labeled goat anti-rat IgG and FITC-labeled goat anti-mouse 
IgG. Cytoskeletons were double stained with (A and C) M4 and rat anti-tubulin and (B and D) M9 and rat anti-tubulin.  The PKC staining 
was viewed under green light (fluorescein) and the tubulin staining was viewed under blue light (rhodamine). PKC staining is shown in 
A (M4) and C (M9) and the tubulin staining is shown in B and D. Bar, 20/~m. 
To our knowledge, this is the first report of the immunofluo- 
rescent localization of PKC with mAbs in intact NIH 3T3 
cells. 
Staining by M4 and M9 in detergent, chelator-treated cells 
indicated that at least part of the whole cell staining may be 
due to association of PKC with components of the cytoskele- 
ton, since actin and intermediate filaments, as well as micro- 
tubules, were present in our cytoskeletal preparations. Our 
results differ from those of Thomas et al. (62), who found 
little or no staining in the cytoskeletal fraction of untreated 
NIH 3T3 cells.  Differences in antibodies and the epitopes 
that they recognize may account for the differences between 
these studies. We found no significant increase in cytoskele- 
tal staining after PMA treatment of the cells.  Our results 
from preparing cytoskeletons with several different buffers 
(see Materials and Methods) suggested that immunofluores- 
cent staining of the cytoskeleton is not a suitable method to 
study  PKC  localization in the nucleus.  Therefore, we ap- 
proached this question of nuclear localization more directly 
in studies using purified nuclei. In other studies, the associa- 
tion of PKC with cytoskeletal proteins has been reported (64, 
65), and PKC has been shown to phosphorylate several cyto- 
skeletal proteins, including talin (40), vinculin (63), and the 
microtubule-associated protein tau  (20).  We have demon- 
strated cytoskeleton-associated Type 3 PKC staining in NIH 
3T3 cells, but further characterization is required to identify 
the specific cytoskeletal components which are involved. The 
cytoskeleton-associated Type 3 PKC in REF52 cells is exam- 
ined in more detail in the accompanying manuscript (26). 
Several studies have shown redistribution, by biochemical 
or immunocytochemical analysis, of PKC after PMA activa- 
tion  (for review,  see reference 46).  After a  10-min PMA 
treatment,  PKC  redistribution  was  observed in  NIH  3T3 
cells  by  immunostaining  with  the  anticatalytic  domain 
mAbs,  M4  and M7.  The staining  pattern with both these 
mAbs covered the cell surface. This apparent PKC redistri- 
bution was  not noted with the antiregulatory domain mAb 
M9.  The M9 staining was clearly different in several ways. 
The Journal of Cell Biology, Volume  109, 1989  690 Figure 4. Isolated nuclei and Type 3 PKC immunofluorescence. (tl) Electron micrograph of isolated 3T3 nuclei. Nuclei were isolated from 
control (B) or PMA-treated (10 rain) (C) cells, fixed and stained with M4. Bar,  10/~m. 
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Control  PMA 
100,000  g  supernatant 
100,000  g  nonnuclear 
membrane pellet 
Nuclear iysate 
pmol/min per mg 
1973  ±  290  110  ±  28 
1478  ±  392  5960  ±  122 
383  ±  188  7021  ±  2250 
Cells were incubated in the presence or absence of 200 nM PMA for 20 min 
at 37°C and subcellular fractions and kinase determinations  were carried out 
as described in Materials and Methods. The results are the average  +  SEM of 
four experiments. 
First, the nuclei remained unstained and the staining did not 
cover the entire cell surface. Second, the M9 staining was 
less uniform throughout the cytoplasm, with an increase in 
perinuclear  staining.  Western blot  analysis of the  PMA- 
treated cells (as well as control cells) showed only the 82-kD 
PKC (Fig. 5 A). The presence of either the 45-kD catalytic 
or the 35-kD regulatory domains, which are detected by M4 
and M9, respectively, was not observed. This result suggests 
that the difference in PKC localization indicated by the stain- 
ing with M4 and M9 is not due to differential localization of 
PKC fragments. 
The different staining patterns observed with the anticata- 
lytic domain mAbs M4 and M7 as compared to the antiregu- 
latory domain mAb M9 may in part be explained by differ- 
ences  in  their  PKC  recognition properties.  Our  previous 
characterization of these mAbs demonstrated that the immu- 
noreactivity of the antiregulatory domain mAbs, which in- 
cludes M9, was sensitive to the PKC conformation, as shown 
by dot blot,  Western blot,  and immunoadsorption assays 
(38). We have also shown that our antiregulatory, but not the 
anticatalytic, domain mAbs inhibit [3H]phorbol  dibutyrate 
(PDBu) binding. This inhibition was sensitive to the phos- 
pholipid concentration used in the binding assay, suggesting 
that the epitope of M9 may be at or near the phospholipid 
binding site. The immunofluorescent staining with M9 sug- 
gests that PMA binding to PKC may lead to a conformational 
change of the regulatory domain such that the epitope recog- 
nized by M9 is no longer accessible, producing a different 
staining pattern than that of the anticatalytic domain mAbs. 
Masking of mAb sites is not unusual; for example, similar 
results have been observed in immunofluorescent staining of 
the fibronectin receptor in chick embryo fibroblasts (2).  In 
cells in which extracellular matrix components are bound to 
the fibronectin receptor, polyclonal antibodies recognizing 
multiple epitopes produce different staining patterns than 
mAbs with epitopes which map to the ligand-binding site of 
the fibronectin receptor. Presumably, binding of the matrix 
components to the receptor reduces the accessibility to the 
mAbs, but not the polyclonal antibodies,  resulting in the 
different staining patterns. Characterization of the epitopes 
recognized by M4, M7, and M9, as well as a better under- 
standing of the relative affinities of each of the mAbs for 
PKC, is required for a full explanation of the observed differ- 
ences in staining patterns. 
Our results demonstrate that PMA treatment decreased the 
level of PKC in the cytosol with a concomitant increase in 
membrane PKC. This treatment also increased the level of 
PKC in the cell nucleus. In the immunofluorescence experi- 
ments with control cells, the nuclei were clearly visible due 
to an apparent lack of staining. These immunocytochemical 
results agreed closely with our biochemical analyses, since 
immunoblotting and PKC activity assays also demonstrated 
little or no nuclear PKC. The immunofluorescent staining of 
PMA-treated cells suggested that PKC might be localized to 
the nucleus after activation, since the staining covered the 
cell surface, including the nuclei. Subsequently, we showed 
by three criteria that PMA treatment specifically increased 
PKC in the nucleus: (a) immunofluorescent staining in iso- 
lated nuclei increased;  (b)  Western blots showed that our 
mAb detected only one protein, the 82-kD PKC, whose level 
increased in nuclear lysates from PMA-treated cells; and (c) 
PKC activity increased in nuclear lysates. Our results are the 
first demonstration using three different criteria that the ac- 
tivity and amount of a  specific isoform, Type 3 PKC, in- 
creases in the nuclei of 3T3 cells. The brevity of the treat- 
ment period suggests that this is a rapid, primary event in 
PKC  activation.  Although our  Western  blot  experiments 
demonstrated that PKC localized to the nuclear envelope, we 
do not yet know whether the PKC is located on the inside 
or the outside of the nucleus. Electron microscopy experi- 
ments will help resolve this issue.  Our further experiments 
will also address whether agents,  such as platelet-derived 
growth factor, which produce diacylglycerols in NIH 3T3 
cells, will also result in PKC nuclear localization. 
Evidence for or against nuclear PKC localization has been 
sought in several different cell types and tissues. The results 
of these studies have been diverse,  perhaps  reflecting the 
wide range of cell types and experimental protocols used, 
which include both reconstituted systems as well as intact 
cells (5, 34, 44). In some cases, no evidence for nuclear PKC 
could be found. Halsey et al. (17) showed increased perinu- 
clear staining in PMA-treated 3T3-L1  cells using a  poly- 
clonal antibody to PKC. However,  PKC activity was asso- 
ciated only with nonnuclear membranes and not with the 
nuclear fraction. Jensen and Sando (27) were unable to dem- 
onstrate either [3H]PDBu binding or PKC activity in nuclei 
of either untreated or phorbol ester-treated EL4 mouse thy- 
moma cells. In contrast, evidence for nuclear PKC has been 
demonstrated in other cell types. Nuclei isolated from bryo- 
statin-treated HL-60 cells bind [3H]PDBu  (36)  and Fields 
et al. (13) reported that short-term treatment with bryostatin, 
but not PDBu, increases calcium-dependent kinase activity 
in the nucleus of HL-60 cells. Kiss et al. (34) reported that 
PMA treatment of HL-60 cells for 2  d  increases nuclear 
PKC. In B lymphocytes, both Ia-binding ligands and cAMP 
increase nuclear PKC activity and PKC levels (4).  Thomas 
et al. (62) used a polyclonal anti-PKC Ab to show increased 
nuclear PKC levels in PMA-treated NIH 3"1"3 cells. The anti- 
bodies used in these last two studies were not characterized 
as to their type specificity.  We found in our studies that im- 
munocytochemical staining of the nucleus in PMA-treated 
cells was dependent on the mAb we used. Thus, immunocy- 
tochemical demonstration of PKC in localization studies may 
be highly dependent on the antibodies used and the epitopes 
that they recognize. Overall, these results are consistent with 
the hypothesis that the localization of PKC to the nucleus 
may be cell and/or isotype specific. 
Our fractionation studies demonstrated clearly that Type 
3 PKC is located in the nuclear envelope. This fraction has 
been shown to consist of the inner and outer nuclear mem- 
branes, pore complexes, and the lamina, a network of lamin 
The Journal of Cell Biology, Volume  109, 1989  692 Figure 5. Western blot of 3T3 cell fractions. Cell fractions were im- 
munoblotted using mAb M4 for A and B. For C and D, the blot was 
first probed with M4 (C), erased as described  in Materials and 
Methods, and reprobed with the lamin B antibody (D). (A) Aliquots 
(100 #g) from (lane 1) cell iysate from control cells and (lane 2) 
lysate from cells treated for 10 min with PMA.  (B) Aliquots (50 
/zg) of 100,000-g supernatant from (lane 1 ) control cells and (lane 
2) PMA- (10 min) treated cells; 100,000-g (nonnuclear) pellet from 
(lane 3) control cells and (lane 4) PMA-treated cells. (C and D) 
Aliquots (50 #g) of (lanes 1 and 2) nuclear lysate, (lanes 3 and 4) 
DNase/RNase extract, (lanes 5 and 6) 1.6 M NaC! extract, (lanes 
7and 8) nuclear envelope fraction from 0.7 x  l07 cells, and (lane 
9) rat brain PKC (5/~g). Lanes 1, 3, 5, and 7, control cells; lanes 
2, 4, 6, and 8, PMA-treated cells. 
proteins between the inner nuclear membrane and chromatin 
(32, 45). Lamin B has been shown to bind intermediate fila- 
ments such as vimentin, and several researchers have sug- 
gested that the cell surface is linked to the nucleus via inter- 
mediate filament attachments, forming a continuous cellular 
network (14,  16). The nuclear envelope also contains a num- 
ber of enzymes, including RNA-activated NTPase (58), cy- 
clooxygenase, isoforms of cytochrome P-450, and phospho- 
protein phosphatases  (42,  54).  The localization of several 
different receptors, such as steroid, thyroid and insulin has 
been reported, as well as the demonstration of polyphospho- 
inositide metabolism,  suggesting that the nuclear envelope 
may be a dynamic structure involved in signal transduction 
pathways (7,  39,  66). 
The exact role of PKC in the nucleus is not yet known. 
Phorbol esters affect the transcription of many genes, includ- 
ing  c-fos,  plasminogen activator, ornithine decarboxylase, 
and interferon (9, 28, 29, 37). PMA-stimulated phosphoryla- 
tion of a variety of nuclear proteins has been reported, in- 
cluding histones (3,  51),  lamin B (13, 19),  matrix proteins 
(41), and DNA topoisomerase II (55). Most of these studies 
have used  reconstitution systems,  and  only some of these 
proteins, such as lamin B, are located in the nuclear enve- 
lope.  Thus, the physiological PKC nuclear substrates have 
not been identified. The PMA-induced phosphorylation of 
intranuclear proteins such as histones may result from the ac- 
tion of a  secondary kinase,  or perhaps PKC can associate 
with other nuclear compartments. Using a short duration of 
PMA treatment,  we found localization only in the nuclear 
envelope fraction. Whether longer PMA treatment or other 
PKC activators result in similar localization is an area of fur- 
ther  investigation.  The  exact  mechanism  by  which  PKC- 
induced changes in phosphorylation leads to alterations in 
gene expression is unknown. PKC-stimulated in vitro phos- 
phorylation of RNA polymerase II results in an increase in 
binding to GTP and an increase in the initial rate of RNA 
synthesis (6). This may be one way by which PKC could alter 
gene expression. Phosphorylation and activation of enhancer 
proteins that bind to phorbol ester responsive elements in 
DNA could serve as another regulatory mechanism (8,  10, 
11, 48, 52, 53, 61). Our results suggest that Type 3 PKC may 
be one of the isozymes involved in these processes. 
Our results in REF52 cells demonstrate PKC localization 
to the specialized area of the cell surface known as the adhe- 
sion plaque (26).  Like the nuclear envelope, the plaque is 
also a dynamic structure associated with signal transduction. 
Taken  together,  these  data  in  NIH  3T3  and  REF52  cells 
showing Type 3 PKC association with cytoskeletal and nu- 
clear components provide a  framework for understanding 
function. In future experiments, we will determine if PKC 
Leach et al, lmmunocytochemical Localization  of PKC in NIH 3T3 Cells  693 substrates are found in these areas, and furthermore, if phos- 
phorylation can be blocked with Type 3 PKC-specific inhibi- 
tots such as M4. 
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